Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (I54.F)

1.0200 -0.0400 (-3.77%) At close: 03:29PM CEST

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

12 Baoshen South Street
Daxing Bio-Medicine Industry Park Daxing District
Beijing
China
86 10 5696 7680
https://biocytogen.com.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,066

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yuelei Shen Ph.D.	Chairman of the Board, CEO & GM	264.39k	N/A	1970
Dr. Jian Ni	Executive Director	N/A	N/A	1972
Dr. Haichao Zhang	Senior Operation Director of Animal Center & Executive Director	129.75k	N/A	1980
Mr. Bin Liu	CFO & Deputy GM	N/A	N/A	1969
Dr. Yi Yang	Chief Scientific Officer & Deputy GM	N/A	N/A	1978
Dr. Chaoshe Guo	VP of Marketing & Deputy GM	N/A	N/A	1971
Ms. Chunli Sun	Director of Human Resources & Supervisor	N/A	N/A	1980
Ms. Yan Li	Chairman of the Supervisory Committee & Director of the President's Office	N/A	N/A	1989
Dr. Qingcong Lin	Deputy GM & CEO of Biocytogen Boston Corp.	N/A	N/A	1965
Mr. Yongliang Wang	Deputy GM, Joint Company Secretary & Chief Secretariat Officer	N/A	N/A	1985

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; and license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.

Corporate governance

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.